Bio-Rad Laboratories, Inc. (BIO)
Valuation Overview•Is Bio-Rad Laboratories, Inc. Overvalued or Undervalued?
Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
Moderate quality score of 56/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. This is paired with healthy capital returns, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
BIO struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company is facing top-line contraction (-2.7% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 9.2%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $592.1M | +0.7% | -2.7% | +0.3% | +2.5% | |
| EBITDA | -$677.5M | — | -10.3% | — | — | |
| Net Income | -$527.1M | +141.2% | — | — | +21.0% | |
| EPS (Diluted) | $-19.55 | +142.6% | — | -26.1% | +22.3% | |
| Free Cash Flow | $78.1M | +40.7% | +67.1% | -4.7% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 51.9% | 53.1% | 54.2% | 54.5% |
| Operating Margin | 9.2% | 11.2% | 13.6% | 9.8% |
| Net Margin | 6.5% | -22.1% | -10.0% | 19.8% |
| FCF Margin | 13.8% | 11.0% | 10.8% | 9.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $1.99 | $1.89 | -5.0% | ||
| Q1'26 | $2.57 | $2.51 | -2.3% | ||
| Q4'25 | $2.30 | $2.26 | -1.7% | ||
| Q3'25 | $1.93 | $2.61 | +35.2% | ||
| Q2'25 | $1.73 | $2.54 | +46.8% | ||
| Q1'25 | $2.86 | $2.90 | +1.4% | ||
| Q4'24 | $1.28 | $2.01 | +57.0% | ||
| Q3'24 | $2.12 | $3.11 | +46.7% |
Total return is +21.7% (1Y), lagging the benchmark by -3.2%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -7.5% | -16.8% | — |
| 1Y | +21.7% | -3.2% | — |
| 3YCAGR | -8.7% | -28.0% | — |
| 5YCAGR | -14.6% | -26.8% | — |
| 10YCAGR | +7.0% | -6.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Bio-Rad Laboratories, Inc. (BIO) valuation, health, and returns.
Bio-Rad Laboratories, Inc. is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Slightly expensive versus peers compared to industry peers. overvalued (implying -50.5% downside from DCF intrinsic value of $139.87)
Bio-Rad Laboratories, Inc. has multiple valuation anchors: DCF Intrinsic Value: $139.87 | Peer Relative Fair Value: $252.37 | Wall Street Analyst Target: $321.67 (implying +13.9% upside). A convergence of these signals offers higher conviction.
Bio-Rad Laboratories, Inc. displays fair financial health with a composite quality score of 56/100, supported by a Altman Z-Score of 2.9 (grey zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 2.6%.
Bio-Rad Laboratories, Inc. returns capital via buybacks instead of dividends, carrying a 3.9% buyback yield and reducing outstanding shares by -3.3% in the last 12 months.
Bio-Rad Laboratories, Inc.'s current growth trajectory is Accelerating. The company achieved +0.7% 1Y revenue growth and +142.6% 1Y EPS growth, compared to its 3Y revenue CAGR of -2.7%.
Wall Street consensus is Buy based on 14 analysts, beating EPS expectations in 67% of recent quarters with a -3-quarter streak. The consensus price target represents a +13.9% change from current levels.
Investment risks for Bio-Rad Laboratories, Inc. include: -28.9% 1-year max drawdown. Volatility risk is characterized by a beta of 0.72x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.